Clinical Trial Update: Efficacy and Safety of Bevacizumab for the Treatment Hemorrhagic Hereditary Telangiectasia (HHT) Associated With Severe Hepatic Vascular Malformations. Phase II Study [Phase 2]

View source ↗

Summary

Phase II trial evaluating bevacizumab for efficacy and safety in hereditary hemorrhagic telangiectasia with severe hepatic vascular malformations. The update re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Hemorrhagic Telangiectasia

Drugs mentioned

• Bevacizumab (Avastin) (bevacizumab)

Snippet

Sponsor: Hospices Civils de Lyon | Conditions: Hemorrhagic Hereditary Telangiectasia | Phase 2 | Status: COMPLETED